Ligand Pharmaceuticals | LGND - Ebitda


Ligand Pharmaceuticals reported $74.27M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.8B 1.25B Sep/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
Baxter International USD 474M 165M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Enviri Corporation USD 70.13M 4.29M Dec/2025
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.93B 154M Sep/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -80.97M 93.7M Sep/2026
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -85.24M 20.71M Jun/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
MacroGenics USD -64.54M 34.34M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Pacira USD 48.67M 8.43M Jun/2026
Pfizer USD 6.36B 350M Sep/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 41.24M 2.72M Sep/2026